Abstract 12205: Prognosis After Endovascular Treatment in Claudicant Patients With Iliofemoral Artery Disease
Background: The natural history of patients with intermittent claudication (IC) has been reported. However, little is known about prognosis of claudicant patients after endvascular therapy (EVT).
Methods: This study was performed as a large-scale multicenter, retrospective registry. A total of 2,930 consecutive patients (mean age, 71.5±8.9 years, 78.7% male) with IC treated by EVT for a de novo ilio-femoral lesion were enrolled.
The primary outcome measure was overall survival, and the secondary outcome measure were freedom from major adverse cardiovascular events (MACE; all-cause death, myocardial infarction and stroke), and major adverse cardiovascular and limb events (MACLE; any repeat revascularization for limb and leg amputation in addition to MACE).
Results: The overall survival rate was 97.2%, 90.8%, and 83.4% at 1, 3 and 5 years. The cause of death was cardiovascular in 42.8%. Freedom from MACE (MACLE) was 96.7% (84.5%), 88.6% (68.1%), and 77.3% (58.7%) at 1, 3and 5 years. Elderly age, Dialysis, LV dysfunction, Insulin use, complication of hematoma, Coronary artery disease, SFA plus iliac lesions were found to be positive independent predictors of all-cause death.
ACEI/ARB use, Ca-antagonist use were negative predictor of them. The overall survival rate was significantly higher in the patients with iliac lesion only compared to patients with SFA plus iliac lesions (85.2% vs. 80.8%, P=0.029). The overall survival rate was similar in two groups (85.2% vs.82.9%, P=0.38).
Conclusions: The prognosis after EVT for patients with IC was relative good. However, this decreased with the number of segmental lesions.
- © 2013 by American Heart Association, Inc.